News
-
-
PRESS RELEASE
Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research GmbH has updated its recommendation and price target on Marinomed Biotech AG (ATMARINOMED6) to UNDER REVIEW following the company's announcement of filing for court-supervised restructuring proceedings to address insolvency risk -
-
PRESS RELEASE
EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
Marinomed Biotech AG to apply for court restructuring proceedings without self-administration due to failed negotiations and insolvency risk. Aim to secure financial stability -
-
PRESS RELEASE
Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy
Marinomed Biotech AG partners with Phargentis SA for worldwide licensing of Marinosolv® Technology in Inhalation Therapy, offering advanced drug delivery solutions for respiratory medicine -
-
PRESS RELEASE
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market, targeting niche patient populations and high-need therapeutic areas with a strategic commercial milestone -
-
